PMID- 27263786
OWN - NLM
STAT- MEDLINE
DCOM- 20161223
LR  - 20171018
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 57
IP  - 5
DP  - 2016 May
TI  - [Chronic myeloid leukemia relapsing ten years after allogenic bone marrow 
      transplantation].
PG  - 608-12
LID - 10.11406/rinketsu.57.608 [doi]
AB  - A 58-year-old female was diagnosed with Philadelphia chromosome positive chronic 
      myeloid leukemia (CML) in blast crisis (BC) in 2004. The patient received 
      imatinib, which quickly induced molecular remission, and subsequently underwent 
      bone marrow transplantation (BMT) from an unrelated human leukocyte antigen 
      (HLA)-identical donor. The post-transplant clinical course was essentially 
      uneventful. In 2014, ten years after the BMT, the patient was admitted to our 
      hospital complaining of lymphadenopathy, and blasts were observed in peripheral 
      blood. The patient was diagnosed as having a CML relapse in myeloid BC, with 
      leukemic infiltration in lymph nodes, and was treated with dasatinib. 
      Subsequently, pleural effusion developed and nilotinib was administered, which 
      induced normal blood counts without blasts and partial cytogenetic remission, one 
      month after administration. Six months after the relapse, this patient underwent 
      a second BMT from an HLA-matched unrelated donor. Recent studies have 
      demonstrated the cumulative incidence of CML relapse more than five years after 
      allogeneic hematopoietic stem cell transplantation (allo-HSCT) to be higher than 
      in acute myeloid leukemia. Although rare, the possibility of late relapse should 
      be considered in patients diagnosed with CML after allo-HSCT.
FAU - Hino, Yutaro
AU  - Hino Y
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Doki, Noriko
AU  - Doki N
FAU - Yamamoto, Keita
AU  - Yamamoto K
FAU - Senoo, Yasushi
AU  - Senoo Y
FAU - Sasajima, Satoshi
AU  - Sasajima S
FAU - Sakaguchi, Masahiro
AU  - Sakaguchi M
FAU - Hattori, Keiichiro
AU  - Hattori K
FAU - Kaito, Satoshi
AU  - Kaito S
FAU - Kurosawa, Shuhei
AU  - Kurosawa S
FAU - Harada, Kaito
AU  - Harada K
FAU - Ikegawa, Shuntaro
AU  - Ikegawa S
FAU - Watanabe, Daisuke
AU  - Watanabe D
FAU - Hagino, Takeshi
AU  - Hagino T
FAU - Yoshioka, Kosuke
AU  - Yoshioka K
FAU - Watakabe, Kyoko
AU  - Watakabe K
FAU - Igarashi, Aiko
AU  - Igarashi A
FAU - Najima, Yuho
AU  - Najima Y
FAU - Kobayashi, Takeshi
AU  - Kobayashi T
FAU - Kakihana, Kazuhiko
AU  - Kakihana K
FAU - Sakamaki, Hisashi
AU  - Sakamaki H
FAU - Ohashi, Kazuteru
AU  - Ohashi K
LA  - jpn
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Biopsy
MH  - *Bone Marrow Transplantation
MH  - Female
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/pathology/*therapy
MH  - Middle Aged
MH  - Recurrence
MH  - Time Factors
MH  - Transplantation, Homologous
EDAT- 2016/06/07 06:00
MHDA- 2016/12/24 06:00
CRDT- 2016/06/07 06:00
PHST- 2016/06/07 06:00 [entrez]
PHST- 2016/06/07 06:00 [pubmed]
PHST- 2016/12/24 06:00 [medline]
AID - 10.11406/rinketsu.57.608 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2016 May;57(5):608-12. doi: 10.11406/rinketsu.57.608.